CJC-1295 With DAC vs No DAC: Structure, Naming and Research Differences

1. “With DAC” and “No DAC” should not share an undefined identity field

CJC-1295 naming can create a serious purchasing ambiguity. The original long-acting CJC-1295 research involved an albumin-binding modification designed to extend exposure. Products commercially described as “CJC-1295 No DAC” are offered without that feature and need their own explicit structural specification. The presence or absence of that modification determines which material the buyer is ordering and which research can support its description.

The 2005 development paper described CJC-1295 as a tetrasubstituted human growth hormone-releasing factor 1–29 analog with an added modified lysine at the C-terminus. The reactive group supported bioconjugation with albumin.^[1] This is the molecular context behind the long-acting pharmacology in the subsequent human studies, not a generic property of every product using the CJC name.

For a research buyer, the first question should be structural: what exact sequence, terminal form, and conjugation-related modification is being offered? A quotation that says only “CJC-1295” leaves the central distinction unresolved. A quotation that says “No DAC” still needs the full identity rather than relying on a commercial nickname.

Why this matters beyond nomenclature

Albumin binding changes the exposure question. A long-acting analog and a nonconjugating related peptide can require different sampling schedules, preparation considerations, and interpretation. Their nominal milligrams are not interchangeable units of experimental effect. A paper describing sustained hormone responses to the long-acting molecule should not be used to assign the same duration to a differently modified product.

The long-acting CJC-1295 studies are tied to the albumin-binding molecule. They do not establish the same half-life or response profile for a product labeled “No DAC.”

The chemistry and human evidence below explain which structural details belong in a KivaPep request. Confirm those details before comparing vial strengths or prices, so that the pilot quantity and any later bulk order refer to the same defined material.

2. The albumin-binding design is the reason for the distinction

The original development strategy used a reactive group on a biologically active peptide to form a conjugate with the free thiol associated with Cys34 of serum albumin. The paper investigated several derivatives, their albumin conjugates, stability-related properties, and biological activity. CJC-1295 was selected for further pharmacokinetic evaluation.^[1]

The design uses a chemical feature intended to support bioconjugation; it does not mean that albumin was simply mixed into the vial. Confirm that the sample contains the required reactive modification, since that feature is part of both its molecular identity and the behavior the experiment is intended to examine.

What the structural description needs to preserve

• Backbone: The specified growth hormone-releasing factor analog sequence.
• Substitutions: The intended amino-acid changes rather than a generic parent-sequence label.
• Terminal features: The exact terminal form and any added residue or linker.
• Reactive modification: The group responsible for the intended albumin-conjugation behavior.

The development paper described an added Nε-3-maleimidopropionamide derivative of lysine at the C-terminus.^[1] A shortened description that counts only the parent 1–29 segment while omitting the added feature can create confusion in an expected-mass calculation or a supplier comparison. The complete offered structure should control the specification.

A non-DAC related peptide may still be a legitimate research material for a different question. The modification changes the experimental question, so selection should be based on the intended exposure behavior and the structure required to investigate it. A project concerned with transient receptor stimulation should not be supplied a long-acting conjugating analog without review, and the reverse substitution is equally consequential.

For a laboratory, the design also raises questions about the assay medium and albumin context. An isolated receptor assay, an albumin-containing system, and an in-vivo exposure study do not examine the same stage of the molecule’s behavior. The methods should make those conditions explicit before results are compared.

3. What the long-acting human studies reported

The 2006 ascending-dose investigation comprised two randomized, placebo-controlled, double-blind studies in healthy adults, with study durations of 28 and 49 days. It examined pharmacokinetics, growth hormone and IGF-I responses, and safety observations for the long-acting CJC-1295 analog.^[2] These were not studies of a generic “No DAC” product.

The authors reported an estimated half-life of 5.8–8.1 days. After a single administration, mean growth hormone and IGF-I measurements remained increased over extended observation periods under the studied conditions. The paper also reported evidence of cumulative effects with repeated administration.^[2] These findings explain why the albumin-binding design became central to the molecule’s research identity.

Hormone response is not the same as a physique outcome

A change in growth hormone or IGF-I is a measured endocrine response. It does not automatically quantify muscle gain, fat loss, recovery, or a long-term health outcome. Those endpoints require their own evidence. A research buyer should be able to describe the hormone data without attaching unrelated promises to it.

The same restraint applies to safety interpretation. The absence of serious adverse reactions reported in a particular small study is not proof that every population, regimen, or material is safe. It is a finding within the study’s scope. A supplier’s purity claim does not expand that scope.

Use the 5.8–8.1-day figure only with its source and long-acting molecule identity. Do not transfer it to an unspecified vial or a product lacking the studied modification.

4. Preserved pulsatility does not mean every pulse became larger

The later pulsatility study used frequent blood sampling over an overnight 12-hour period before and after long-acting CJC-1295 administration in healthy men. It reported preserved growth hormone pulsatility alongside increased trough and mean secretion measures.^[3] This is a more specific finding than the broad phrase “boosts natural pulses.”

The investigators reported that the frequency and magnitude of secretory pulses were unaltered in that analysis, while basal trough levels increased substantially. The higher overall exposure was therefore associated with the changed baseline in this analysis, not an increase in pulse size or frequency. Preserve that distinction when describing the hormone profile measured in the paper.

A hormone profile has several dimensions

Mean concentration, trough concentration, pulse frequency, pulse magnitude, and area under the curve describe different features. Two profiles can have a similar mean and different temporal patterns. Conversely, a preserved pulse pattern can coexist with a higher baseline. The sampling schedule and analytical method determine which features can be estimated reliably.

For a research project comparing long-acting and non-DAC materials, this is especially relevant. A sparse sampling schedule may miss temporal differences that are central to the hypothesis. Choosing time points solely because they are convenient can make the experiment unable to answer its own question.

The study also illustrates why endocrine measurements should not be converted into a personal administration plan. The methods describe an investigation in a defined population, with oversight and a specified test article. They do not provide instructions for an independently supplied research material.

The cited regimens and hormone measurements describe research. They are not guidance for self-administration, combining secretagogues, or substituting a No-DAC material for a long-acting product.

For KivaPep, the commercial implication is to ask what exposure question the buyer intends to study. The correct material, documentation, and quantity can then be discussed in relation to that question rather than selected from an ambiguous product nickname.

5. With DAC versus No DAC is an experimental design decision

A project studying albumin-associated exposure needs the relevant modified molecule and a method that can examine that behavior. A project studying a nonconjugating related peptide needs that exact alternative defined. A direct comparison may need both, but it should be designed as a comparison of structurally distinct test articles.

Equal mass is not automatically an appropriate matching basis. The structural modifications change molecular composition, and exposure behavior may differ. Even equal molar amounts do not establish equivalent pharmacological duration. The protocol should explain whether it is matching concentration, receptor response, or another variable and why that choice is useful.

Do not hide a second product inside the comparison

A blend with another secretagogue introduces another variable. It cannot be treated as a substitute for a single-compound CJC experiment simply because the blend is popular. If a combination is the actual research question, each component’s identity and amount should be stated, and the design should include the controls needed to distinguish their contributions.

The same applies to formulation differences. Solvents, additives, and preparation history can affect the test system. A comparison of molecules should not accidentally become an uncontrolled comparison of vehicles. Ask for the actual offered presentation and decide whether it is suitable before ordering.

Once the central research question is settled, identify the required material form and supporting information in the brief. State whether the request concerns the original long-acting analog, a non-DAC related product, or a blend. The supplier can then confirm the structure and presentation without interpreting the abbreviated name on the buyer's behalf.

6. The specification should resolve what the nickname leaves open

A complete specification begins with the structure rather than the marketing abbreviation. It should identify the sequence, substitutions, terminal form, added residues or linkers, and whether the albumin-binding feature is present. The expected analytical identity should be consistent with that description. A mass value copied from a different form is a warning that the record needs clarification.

HPLC area purity and a matching mass can contribute useful evidence, but neither should be described as proving every functional property of a reactive modification. If conjugation behavior is important to the project, ask what information is available and what the laboratory needs to evaluate independently. Choose the analytical scope according to the structural and functional questions that the intended use requires the laboratory to resolve.

Content basis also matters when comparing vial strengths. The total dried mass and the assigned peptide amount can differ depending on composition and reporting convention. A quantitative experiment needs the latter defined well enough to prepare its intended concentration. A product label alone may not provide that information.

For stability, request conditions supported for the actual form. Do not assume a claim for one CJC-related molecule applies to another, or invent a prepared-solution lifetime from the long-acting clinical half-life. Chemical stability in a container and pharmacokinetic persistence in a biological system are different measurements entirely.

7. A pilot order that prevents the wrong bulk purchase

In the first message to KivaPep, request the intended CJC-related material and ask for confirmation of its DAC status and full structure. An abbreviated request such as “send CJC” leaves the offered identity unresolved. Add the intended research category, preferred presentation, initial quantity, follow-up volume, and destination. That gives the supplier enough context to provide a meaningful current offer.

Resolve these items before scaling

• Identity: Does the offered structure match the project’s required form?
• Evidence: Are the analytical records linked to the offered lot?
• Preparation: Can the laboratory use the presentation in its planned method?
• Continuity: Can later shipments maintain the accepted specification?

A pilot should leave enough retained material for repeat analysis. If the first experiment produces an unexpected response, the retained sample can help separate material identity, preparation, and assay questions. Consuming the entire shipment at once can make that investigation much harder.

When comparing quotations, align the exact structure, content basis, testing scope, packaging, and delivery responsibilities. A lower price for a different CJC-related molecule is not a lower price for the same product. The difference may still be commercially relevant, but it needs a scientific decision rather than a purchasing assumption.

For private-label or blend projects, agree on the technical composition before approving artwork. A shortened front label can be convenient, but the full specification should remain accessible and consistent. If a blend contains a non-DAC material, it should not inherit long-acting CJC-1295 pharmacokinetic claims merely because the name appears in both contexts.

Use the accepted pilot to establish the reorder specification, including the material identity and the records required with each lot. Competitive quotations can then be assessed against that specification. Resolving the nomenclature before shipping reduces the risk that a structural difference will first become apparent through an unexpected experimental result.

8. The right comparison begins with the modification

The original CJC-1295 development and human studies describe a long-acting albumin-binding analog with a specific molecular design.^[1][2][3] A product labeled No DAC should be evaluated as its own explicitly defined material, not as the same molecule with a shorter marketing description. That is the central distinction a research buyer needs to carry into the order.

The evidence also supports a more careful account of hormone dynamics. Sustained responses and preserved pulsatility were measured under defined conditions, and the pulsatility study did not show that every pulse became larger or more frequent. Include those details in the evidence summary so that the reported increase in overall exposure is not attributed to pulse changes the study did not observe.

Before approving the purchase

Match the source paper’s molecule with the requested and offered structures. Check the DAC status, terminal features, expected identity, content basis, and analytical scope. Define the preparation and sampling approach for the experiment. Then compare the complete commercial offer, including lot continuity and delivery requirements.

For an established laboratory, this may be a short confirmation against an existing specification. For a new buyer, it may require one additional conversation before choosing a vial size. The confirmation lets the team check for a structural mismatch before investigating a later response as an unexpected biological effect.

KivaPep can discuss current pilot and bulk supply against that clarified requirement. The most useful inquiry identifies the exact form and the evidence needed for evaluation, rather than relying on a product nickname to carry information it does not contain.

Confirm the full structure before comparing CJC-1295 With DAC and No DAC. The albumin-binding modification changes the research question, and the long-acting clinical data do not automatically apply to the non-DAC offer.

Explore the KivaPep product catalog, or return to the CJC-1295 NO DAC research hub to follow this product's expanding evidence and supply guides.